Despite regular blood transfusion and iron chelation therapy, growth impairment and pubertal delay are commonly seen in children and adolescents with transfusion-dependent Beta thalassaemia major (BTM) and sickle cell disease (SCD). We evaluated growth parameters and endocrine disorders in relation to the liver iron concentration (LIC) assessed by the Ferriscan® method in a cohort of adults with SCD (n=40) and BTM (n=52) receiving blood transfusions and iron chelation therapy since early childhood. Before transfusion, hemoglobin concentration had not been less than 9 g/dl in the past 12 years; subcutaneous daily desferrioxamine was administered for all of them since early childhood (2-5 years of age). All patients were shifted to oral therapy with deferasirox iron chelation, 20 mg/daily for the past 5 years. BTM patients with higher LIC (>15 mg Fe/g dry weight) had significantly shorter stature, lower insulin-like growth factor-I SDS (IGF-I SDS), higher alanine transferase (ALT) and serum ferritin concentrations compared to thalassemic patients with lower LIC. Patients with SCD with LIC >8 mg Fe/g dry weight had significantly shorter stature, lower IGF-I SDS and higher ALT compared to SCD patients with lower LIC. Patients with BTM had significantly shorted final height (Ht-SDS), IGF-I SDS and FT4 level compared to patients with SCD. LIC and mean fasting blood glucose (FBG) were significantly higher in patients with BTM compared to those with SCD. The linear regression analysis showed a significant correlation between LIC and serum ferritin level in SCD and BTM. LIC and serum ferritin level were also correlated significantly with IGF-I level in patients with BTM. LIC was correlated significantly with ALT in patients with BTM. In conclusion, the prevalence of endocrinopathies especially hypothyroidism, DM, and hypogonadism were significantly higher in BTM patients versus SCD patients and higher in patients with higher LIC versus those with lower LIC. These complications occurred less frequently, but still considerable, in chronically transfused patients with SCD. (www.actabiomedica.it) 
Introduction
Iron overload is a common clinical problem, arising from iron hyperabsorption (such as hereditary hemochromatosis or thalassemia intermedia syndromes) or through regular blood transfusion therapy for conditions such as thalassemia major, sickle cell disease (SCD) and myelodysplastic syndrome (1, 2) . Under normal iron conditions, apotransferrin (transferrin without bound iron) exists in excess, with only 25% of the binding sites carrying iron to the bone marrow, liver, and other tissues. As the liver is the dominant storage organ for excess iron, hepatocellular iron uptake of transferrin-bound iron is preserved even in iron overload conditions. In severe iron overload, however, transferrin binding capacity becomes saturated and low molecular weight non-transferrin-bound iron (NTBI) or "free" iron species appear. The heart and endocrine glands are sensitive to chronic exposure to NTBI species (1) (2) (3) .
In SCD iron overload occurs later than in thalassemia major and endocrine disorders are less common (2) . Recent reports, however, have documented that endocrine dysfunctions are commonly encountered in children and adolescents with SCD (4-6), and vitamin D deficiency is the most commonly documented endocrine disorder (6) .
The biochemical markers of the iron metabolism disorders include an elevated concentration of iron and serum ferritin (SF) and transferrin saturation in plasma. However, these parameters are not always specific for body iron load (7) . Furthermore, SF can be unreliable in SCD due to the inflammatory nature of the condition, even in the steady state (8) .
In a cross-sectional study of 27 children (10.9±3.3 years) with SCD who had received chronic transfusion therapy without chelation, transfusion volume provided more insight on liver iron content (LIC) than serum iron markers (9) . Therefore, treatment with iron chelation and monitoring of transfusional iron overload in SCD aim principally at controlling liver iron, thereby reducing the risk of cirrhosis and hepatocellular carcinoma (2) .
Monitoring of liver iron concentration pretreatment and in response to iron chelation therapy by a noninvasive measurement of liver iron concentration (LIC) using validated and widely available magnetic resonance imaging (MRI) techniques reduces the risk of under-or overtreatment (2) . A standardized and validated MRI method is now registered in Europe and the United States (Ferriscan®), with reproducible relationship between the value (R2) by MRI and LIC by biopsy over a clinically useful range.
Ferriscan® enables locally acquired data to be analyzed at a central facility and is potentially available in any hospital with an MRI scanner and with minimal training of local staff (10) (11) (12) .
The aim of present study was to study the growth parameters, IGF-I and endocrine functions in patients with BTM and SCD receiving blood transfusion and iron oral chelation therapy (OIC) with deferasirox in the last 5 years. Iron overload was assessed in both groups of patients by serum ferritin and Ferriscan®.
Patients and Methods
We performed a cross-sectional analysis of linear growth (height and height SDS (Ht-SDS), weight, body mass index (BMI), and endocrine testing in 2 groups of transfusion dependent adult patients with BTM (n=52) and SCD (n=40) who completed their puberty and attained their final adult height (FA-Ht). Before transfusion, hemoglobin concentration had not been less than 9 g/dl in the past 12 years; subcutaneous daily desferrioxamine was administered for all of them since early childhood (2-5 years of age). All patients were shifted to oral therapy with deferasirox iron chelation, 20 mg/daily for the past 5 years. Blood transfusion therapy in SCD was initiated during childhood either for therapy (typically for life-threatening SCD related complication and anemia) or for prophylaxis, to decrease the incidence of specific SCD related complications. In BTM, all patients had started their blood transfusion during their first 2 years of life for correction of severe anemia.
Lab. investigations, using commercial radioimmunoassay included the measurement of fasting serum concentration of free thyroxine (FT4), thyrotropin (TSH), IGF-I, and gonadotrophins (LH and FSH), and serum cortisol.
Fasting blood glucose and hepatic function (ALT, AST and ALP) were also assessed. Liver iron content was measured using the FerriScan® R2-MRI method (7) . Ethical approval for the study was obtained by Ethical Committee of Hamad General Hospital, which were in accordance, by the Declaration of Helsinki.
Student t test and ANOVA test were used to compare the growth and lab. Data among the different groups when the data was normally distributed and Wilcoxon rank test was used when the data was not normally distributed. Linear regression equation was used to study possible relations between different factors and FA-Ht.
Results
Patients with BTM were categorized in 3 groups according to their LIC (Table 1) . Thalassemic patients with severe hepatic iron overload had significantly shorter stature, lower IGF-I SDS and higher ALT, AST and serum ferritin concentrations compared to BMT with mild-moderate LIC. The prevalence of short stature and low IGF-I SDS, diabetes mellitus insulin dependent (DM), and hypogonadism was significantly higher in the BTM group with severe hepatic iron overload compared to the other groups with lower LIC (Table 2) .
Patients with SCD were categorized in 2 groups based on their LIC values (Table 3 and 4) . Patients with moderate LIC (>8 mg Fe/g dry weight) had significantly shorter stature, lower IGF-I SDS and basal TSH, and higher ALT compared to SCD patients with mild LIC (<8 mg Fe/g dry weight). The prevalence hypothyroidism was significantly higher in SCD patients Table 1 . Growth, biochemical and endocrine parameters in adult patients with BTM according to their degree of LIC. Abbreviations = BTM: β-thalassemia major, LIC: liver iron content, FT4: free thyroxine, TSH: thyrotropin, LH and FSH: Luteinizing hormone and Follicle-stimulating hormone, PTH: paratormone, IGF-I SDS: insulin-like growth factor-1 standard deviation score, Ht-SDS : height SDS, BMI: body mass index, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase, FBG:fasting blood glucose, Cort: serum cortisol. with higher LIC. The prevalence of short stature and low IGF-I SDS, DM, impaired fasting glucose (IFG) and hypogonadism was non-significantly higher in the SCD group with higher LIC compared to the group with lower LIC (Table 4) .
Patients with BTM had significantly lower Ht-SDS level compared to patients with SCD. LIC, serum ferritin and ALT were significantly higher in patients with BTM compared to those with SCD ( Table  5 ). The prevalence of endocrinopathies namely hypothyroidism, DM, and hypogonadism was significantly higher in BTM patients versus SCD patients (Table  6 ). No cases of hypocortisolim or hypoparathyroidism were documented in both groups.
The linear regression analysis showed a significant correlation between LIC and serum ferritin level in SCD and BTM. LIC and serum ferritin level were also correlated significantly with IGF-I level in patients with BTM. LIC was correlated significantly with ALT in patients with BTM . Age of the patients with SCD and BTM was not correlated significantly with LIC or ferritin levels ( Table 7) . The duration of blood transfusions was not statistically different in patients with BTM (23.5±5.4 years) versus SCD (26.5±8 years) (p> 0.05). 
Discussion
BTM and SCD are important causes of morbidity and mortality worldwide, causing damage and dysfunction in multiple organs. The complications of these diseases are numerous, affect almost every organ and/or tissue in the body and vary considerably among patients over the time (2-6, 13-15).
Longitudinal studies have reported that the prevalence of endocrine complications has declined in the last few decades thanks to more effective iron chelation and earlier age of first exposure to chelation treatment (16) . However, a cross-sectional, analytic study was carried out on 43 TM patients aged 45-60 years. The data indicated that 88.4% of adult BTM patients of this advanced age group suffered from at least one endocrine complication. The majority of patients developed endocrine complications in the second decade of life when serum ferritin level was very high (above 5,000 ng/ml).
The very high peak level of serum ferritin registered in these patients was probably due to inadequate doses of desferrioxamine in the 1 st years of life, combined with poor compliance to treatment during the peripubertal or pubertal age and increased amount of transfused blood not balanced by increased chelating treatment (17). Overall, the prevalence of endocrine disorders in TM patients is affected by various factors such as: genotype, age, hemoglobin level attained before blood transfusion, degree, type and age at the beginning of chelation therapy, compliance to treatment, presence of associated complications, and zinc deficiency (3, 5, 13-16 ). Therefore, physicians' strategies to optimize chelation therapy include identifying patients who are at risk for developing organ damage, developing chelation plans, promoting compliance, and educating patients (17) .
Our study revealed high prevalence of short stature, hypogonadism, hypothyroidism, DM and IGF-I deficiency in adult patients with BTM. These complications occurred less frequently, but still considerable, in chronically transfused patients with SCD. Because endocrine complications are mostly attributed to iron overload and suboptimal chelation therapy, we compared the final growth and endocrine dysfunctions of BTM (n=52) and SCD (n=40) patients to their LIC, as measured by Ferriscan® method.
Patients with BTM had significantly lower Ht-SDS level compared to patients with SCD. LIC, serum ferritin and ALT concentrations were significantly higher in patients with BTM compared to those with SCD. The prevalence of endocrinopathies namely hypothyroidism, DM, and hypogonadism were significantly higher in BTM patients versus SCD patients. However, the occurrence of significant endocrinopathies in our patients with SCD as well as in other studies proved that SCD patients are unlikely to be completely protected from the extrahepatic effects of iron overload.
The higher prevalence of hypogonadism, DM and IGF-I deficiency in BTM with higher LIC compared to those with lower LIC proves the significant contribution of the degree of iron overload in the pathogenesis of endocrine dysfunction. In accordance with our results, Chirico et al. (18) reported that patients with ferritin values above 1,800 μg/L experienced a significantly faster evolution to hypothyroidism, hypogonadism and multiple endocrinopathies. The intensification of chelation therapy in patients with BTM led to an amelioration of many endocrinopathies including hypothyroidism and hypogonadism (19, 20) .
In general, patients with SCD are not routinely screened for iron overload and receive less iron chelation compared to patients with BTM (21) . In support of these findings, iron overload was present in approximately one-third of 141 adult SCD patients at post mortem (mean age, 36 y), and 7% of deaths were judged to be related to iron overload (21) . In another cohort of 387 young adults with SCD from Atlanta, there were 22 deaths, 45% related to iron overload (22) .
Our understanding of iron overload-related organ damage in patients with SCD is still developing. 25% of our adult patients with SCD had LIC >8 mg Fe/g d/wt. Therefore, it appears necessary to routinely monitor iron status in all patients who have been previously transfused with multiple RBC units over a protracted period of time or are currently undergoing regular transfusions.
Serial measurement of steady-state serum ferritin levels is a relatively robust, convenient, and inexpensive marker of body iron burden. Our study found a significant correlation between serum ferritin level and LIC in adult patients with SCD and BTM denoting that serum ferritin is still a good marker of iron overload in patients with BTM and SCD. In support to our view, in a cohort of adults with non-transfusion dependent SCD, LIC correlated significantly with serum ferritin (23) . In a cross-sectional study of 27 children (10.9±3.3 years) with SCD who had received chronic transfusion therapy without chelation, serum ferritin and total volume of transfusions were correlated significantly with LIC (24) .
Nevertheless, a number of studies have failed to demonstrate a positive correlation of serum ferritin with LIC in patients with SCD (25) (26) (27) (28) (29) .
Although the liver is the primary site of excess iron storage in both patients with SCD and BMT, there were some disparities in the occurrence of endocrine glands injury. In fact, these complications occurred less frequently, but still considerable, in chronically transfused patients with SCD. There are several hypotheses to explain these distinct differences in iron loading and organ toxicity, including differences in intestinal iron absorption and the rate and duration of transfusions as well as the possibility that the chronic inflammatory state associated with SCD is protective against tissue damage (30) . Lower levels of nontransferrin-bound iron (NTBI) in patients with SCD, relative to those seen in patients with BMT, also indicate that there may be intrinsic differences in iron transport and storage between these two populations (31) .
In conclusion, the prevalence of endocrinopathies especially hypothyroidism, DM, and hypogonadism were significantly higher in chronically transfused patients with BTM patients versus SCD patients and were more prevalent in patients with higher LIC versus those with lower LIC. This study confirm that iron overload is an inevitable consequence of long-term transfusion therapy, for which iron chelation therapy is indicated and recommended. All patients who receive RBC transfusions and iron chelation therapy should be regularly monitored and given practical and educational support in order to improve compliance with therapy.
